Suchergebnisse - "Choi, Yoonha"

PubPharm (63)

1

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

enthalten in: Nature | 2024

von Guan, X. | Hu, R. | Choi, Y. | +28

ErratumIn: Nature. 2024 Mar 13;:. - PMID 38480897

2

Publisher Correction : Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

enthalten in: Nature | 2024

von Guan, X. | Hu, R. | Choi, Y. | +28

ErratumFor: Nature. 2024 Mar;627(8004):646-655. - PMID 38418879

3

CLINICAL CLASSIFIERS AND GENOMIC CLASSIFIERS AND USES THEREOF

enthalten in: Europäisches Patentamt | 2024

von KENNEDY GIULIA C | CHOI YOONHA | BABIARZ JOSHUA | +8

4

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer : a phase 1b trial

enthalten in: Nature medicine | 2024

von Desai, J. | Alonso, G. | Kim, S. | +37

5

Author Correction : Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

enthalten in: Nature communications | 2023

von Al-Sawaf, O. | Zhang, C. | Jin, H. | +20

ErratumFor: Nat Commun. 2023 Apr 18;14(1):2147. - PMID 37072421

6

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

enthalten in: The New England journal of medicine | 2023

von Sacher, A. | LoRusso, P. | Patel, M. | +108

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):733. - PMID 37673947

7

PREDICTING TOLERABILITY IN AGGRESSIVE NON-HODGKIN LYMPHOMA

enthalten in: Europäisches Patentamt | 2023

von NIELSEN TINA GERITZ | PAULSON JOSEPH NATHANIEL | SCHNEIDER DANIEL JAY | +4

8

PREDICTING TOLERABILITY IN AGGRESSIVE NON-HODGKIN LYMPHOMA

enthalten in: Europäisches Patentamt | 2023

von NIELSEN TINA GERITZ | PAULSON JOSEPH NATHANIEL | SCHNEIDER DANIEL JAY | +4

9

PREDICTING TOLERABILITY IN AGGRESSIVE NON-HODGKIN LYMPHOMA

enthalten in: Europäisches Patentamt | 2023

von NIELSEN TINA GERITZ | PAULSON JOSEPH NATHANIEL | SCHNEIDER DANIEL JAY | +4

10

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

enthalten in: Nature communications | 2023

von Al-Sawaf, O. | Zhang, C. | Jin, H. | +20

ErratumIn: Nat Commun. 2023 Oct 23;14(1):6724. - PMID 37872229

1
2
3
4
5
6
7
Nächster »
[7]